Top

Published in:

Open Access 01-04-2021 | Amyotrophic Lateral Sclerosis | Review Article

The links between diabetes mellitus and amyotrophic lateral sclerosis

Authors: Rosario Vasta, Fabrizio D’Ovidio, Giancarlo Logroscino, Adriano Chiò

Published in: Neurological Sciences | Issue 4/2021

Abstract

ALS etiology and prognostic factors are mostly unknown. Metabolic diseases and especially diabetes mellitus (DM) have been variously related to ALS. However, pieces of evidence have been variegated and often conflicting so far. This review aims to give an overview of recent contributions focusing on the relationship between DM and ALS. DM seems to reduce the risk of developing ALS if diagnosed at a younger age; conversely, when diagnosed at an older age, DM seems protective against ALS. Such a relationship was not confirmed in Asian countries where DM increases the risk of ALS independently of the age of onset. Interestingly, DM does not affect ALS prognosis, possibly weakening the potential causal relationship between the two diseases. However, since most studies are observational, it is difficult to state the exact nature of such a relationship and several hypotheses have been made. A recent study using Mendelian randomization suggested that DM is indeed protective against ALS in the European population. However, these analyses are not without limits and further evidence is needed. DM is usually the core of a larger metabolic syndrome. Thus, other metabolic changes such as dyslipidemia, body mass index, and cardiovascular diseases should be collectively considered. Finally, hypermetabolism usually found in ALS patients should be considered too since all these metabolic changes could be compensation (or the cause) of the higher energy expenditure.

Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet Lond Engl 377:942–955. https://doi.org/10.1016/S0140-6736(10)61156-7CrossRef

Ingre C, Roos PM, Piehl F et al (2015) Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 7:181–193. https://doi.org/10.2147/CLEP.S37505CrossRefPubMedPubMedCentral

(2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36:S67–S74. https://doi.org/10.2337/dc13-S067

WHO | Global report on diabetes. In: WHO. http://www.who.int/diabetes/publications/grd-2016/en/. Accessed 16 Jan 2020

Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10:75–82. https://doi.org/10.1016/S1474-4422(10)70224-6CrossRef

Brito MD, da Silva GFG, Tilieri EM, Araujo BG, Calió ML, Rosenstock TR (2019) Metabolic alteration and amyotrophic lateral sclerosis outcome: a systematic review. Front Neurol 10:1205. https://doi.org/10.3389/fneur.2019.01205CrossRefPubMedPubMedCentral

Mitchell CS, Hollinger SK, Goswami SD, Polak MA, Lee RH, Glass JD (2015) Antecedent disease is less prevalent in amyotrophic lateral sclerosis. Neurodegener Dis 15:109–113. https://doi.org/10.1159/000369812CrossRefPubMedPubMedCentral

Mariosa D, Kamel F, Bellocco R, Ye W, Fang F (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 22:1436–1442. https://doi.org/10.1111/ene.12632CrossRefPubMedPubMedCentral

Kawada T (2016) Type 2 diabetes and amyotrophic lateral sclerosis. Eur J Neurol 23:e9. https://doi.org/10.1111/ene.12893CrossRefPubMed

10.

Mariosa D, Fang F (2016) Response to the letter “Type 2 diabetes and amyotrophic lateral sclerosis.”. Eur J Neurol 23:e26. https://doi.org/10.1111/ene.12928CrossRefPubMed

11.

Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72:905–911. https://doi.org/10.1001/jamaneurol.2015.0910CrossRefPubMedPubMedCentral

12.

Sun Y, Lu C-J, Chen R-C, Hou WH, Li CY (2015) Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol 25:445–451. https://doi.org/10.2188/jea.JE20140176CrossRefPubMedPubMedCentral

13.

Tsai C-P, Lee JK-W, Lee CT-C (2019) Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol 266:2233–2243. https://doi.org/10.1007/s00415-019-09405-xCrossRefPubMed

14.

Seelen M, van Doormaal PTC, Visser AE, Huisman MHB, Roozekrans MHJ, de Jong SW, van der Kooi AJ, de Visser M, Voermans NC, Veldink JH, van den Berg LH (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261:1949–1956. https://doi.org/10.1007/s00415-014-7445-1CrossRefPubMed

15.

D’Ovidio F, d’Errico A, Carnà P et al (2018) The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol 25:164–170. https://doi.org/10.1111/ene.13465CrossRefPubMed

16.

Logroscino G (2015) Motor neuron disease: are diabetes and amyotrophic lateral sclerosis related? Nat Rev Neurol 11:488–490. https://doi.org/10.1038/nrneurol.2015.145CrossRefPubMed

17.

Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ (2013) Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81:1222–1225. https://doi.org/10.1212/WNL.0b013e3182a6cc13CrossRefPubMedPubMedCentral

18.

Jawaid A, Brown JA, Schulz PE (2015) Diabetes mellitus in amyotrophic lateral sclerosis: Dr. Jekyll or Mr. Hyde? Eur J Neurol 22:1419–1420. https://doi.org/10.1111/ene.12660CrossRefPubMed

19.

Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, Petri S (2013) Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 20:647–654. https://doi.org/10.1111/ene.12015CrossRefPubMed

20.

Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N, Cudkowicz M, Miller TM (2015) Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve 52:339–343. https://doi.org/10.1002/mus.24688CrossRefPubMedPubMedCentral

21.

Jawaid A, Schulz PE (2015) Pre-morbid type 2 diabetes mellitus as a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve 52:690–691. https://doi.org/10.1002/mus.24758CrossRefPubMed

22.

Paganoni S, Schoenfeld D, Shui A, Cudkowicz M, Miller TM (2015) Reply: To. Muscle Nerve 52:691. https://doi.org/10.1002/mus.24760CrossRefPubMed

23.

Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, Lunetta C, Marinou K, Ticozzi N, Drago Ferrante G, Scialo C, Sorarù G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurrò MR, Sabatelli M, Chiò A, Riva N, Logroscino G, Messina S, Calvo A (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25:861–868. https://doi.org/10.1111/ene.13620CrossRefPubMed

24.

Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, Grassano M, Bersano E, Cammarosano S, Manera U, Parals, Pisano F, Mazzini L, Dalla Vecchia LA, Mora G, Chiò A (2017) Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Front Degener 18:590–597. https://doi.org/10.1080/21678421.2017.1336560CrossRef

25.

Wei Q-Q, Chen Y, Cao B, Ou RW, Zhang L, Hou Y, Gao X, Shang H (2017) Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival. Mol Neurodegener 12:69. https://doi.org/10.1186/s13024-017-0211-yCrossRefPubMedPubMedCentral

26.

Zhang L, Chen L, Fan D (2019) The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China. Amyotroph Lateral Scler Front Degener:1–7. https://doi.org/10.1080/21678421.2019.1704010

27.

Hollinger SK, Okosun IS, Mitchell CS (2016) Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol 7:47. https://doi.org/10.3389/fneur.2016.00047CrossRefPubMedPubMedCentral

28.

Zeng P, Wang T, Zheng J, Zhou X (2019) Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med 17:225. https://doi.org/10.1186/s12916-019-1448-9CrossRefPubMedPubMedCentral

29.

Lim MA, Bence KK, Sandesara I, Andreux P, Auwerx J, Ishibashi J, Seale P, Kalb RG (2014) Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 23:4995–5008. https://doi.org/10.1093/hmg/ddu214CrossRefPubMedPubMedCentral

30.

Borghero G, Pugliatti M, Marrosu F et al (2016) TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiol Aging 43:180.e1–180.e5. https://doi.org/10.1016/j.neurobiolaging.2016.03.028CrossRef

31.

Rosenbohm A, Nagel G, Peter RS, Brehme T, Koenig W, Dupuis L, Rothenbacher D, Ludolph AC, for the ALS Registry Study Group (2018) Association of serum retinol-binding protein 4 concentration with risk for and prognosis of amyotrophic lateral sclerosis. JAMA Neurol 75:600–607. https://doi.org/10.1001/jamaneurol.2017.5129CrossRefPubMedPubMedCentral

32.

Jaronen M, Goldsteins G, Koistinaho J (2014) ER stress and unfolded protein response in amyotrophic lateral sclerosis-a controversial role of protein disulphide isomerase. Front Cell Neurosci 8:402. https://doi.org/10.3389/fncel.2014.00402CrossRefPubMedPubMedCentral

33.

Kanekura K, Suzuki H, Aiso S, Matsuoka M (2009) ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol 39:81–89. https://doi.org/10.1007/s12035-009-8054-3CrossRefPubMed

34.

Shi Y, Park KS, Kim SH, Yu J, Zhao K, Yu L, Oh KW, Lee K, Kim J, Chaggar K, Li Y, Dolphin AC, Catterall WA, Ryu SH, Yang SN, Berggren PO (2019) IgGs from patients with amyotrophic lateral sclerosis and diabetes target CaVα2δ1 subunits impairing islet cell function and survival. Proc Natl Acad Sci U S A 116:26816–26822. https://doi.org/10.1073/pnas.1911956116CrossRefPubMedCentral

35.

Araki K, Araki A, Honda D, Izumoto T, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Hara A, Ikumi K, Kawai K, Ishigaki S, Nakamichi Y, Tsunekawa S, Seino Y, Yamamoto A, Takayama Y, Hidaka S, Tominaga M, Ohara-Imaizumi M, Suzuki A, Ishiguro H, Enomoto A, Yoshida M, Arima H, Muramatsu SI, Sobue G, Katsuno M (2019) TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest 130:3578–3593. https://doi.org/10.1172/JCI124481CrossRef

36.

Jawaid A, Abid A, Schulz PE (2018) Diabetes mellitus and amyotrophic lateral sclerosis: time to bridge the gap between the bench and the bedside. Eur J Neurol 25:3–4. https://doi.org/10.1111/ene.13481CrossRefPubMed

37.

Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ (2011) Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 6:e24189. https://doi.org/10.1371/journal.pone.0024189CrossRefPubMedPubMedCentral

38.

Coughlan KS, Mitchem MR, Hogg MC, Prehn JHM (2015) “Preconditioning” with latrepirdine, an adenosine 5’-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging 36:1140–1150. https://doi.org/10.1016/j.neurobiolaging.2014.09.022CrossRefPubMed

39.

Okamoto K, Kihira T, Kondo T, Kobashi G, Washio M, Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Inaba Y, Nagai M (2007) Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph Lateral Scler Off Publ World Fed Neurol Res Group Mot Neuron Dis 8:300–304. https://doi.org/10.1080/17482960701472249CrossRef

40.

Wills A-M, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M, MDA Clinical Research Network (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Lond Engl 383:2065–2072. https://doi.org/10.1016/S0140-6736(14)60222-1CrossRef

41.

Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE (2010) ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 17:733–739. https://doi.org/10.1111/j.1468-1331.2009.02923.xCrossRefPubMed

42.

Ali O (2013) Genetics of type 2 diabetes. World J Diabetes 4:114–123. https://doi.org/10.4239/wjd.v4.i4.114CrossRefPubMedPubMedCentral

43.

Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17:94–102. https://doi.org/10.1016/S1474-4422(17)30401-5CrossRefPubMed

44.

Auburger G, Gispert S, Lahut S, Omür O, Damrath E, Heck M, Başak N (2014) 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World J Diabetes 5:316–327. https://doi.org/10.4239/wjd.v5.i3.316CrossRefPubMedPubMedCentral

45.

Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VMY, van Deerlin VM, Bonini NM, Gitler AD (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069–1075. https://doi.org/10.1038/nature09320CrossRefPubMedPubMedCentral

46.

Lahut S, Ömür Ö, Uyan Ö, Ağım ZS, Özoğuz A, Parman Y, Deymeer F, Oflazer P, Koç F, Özçelik H, Auburger G, Başak AN (2012) ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 7:e42956. https://doi.org/10.1371/journal.pone.0042956CrossRefPubMedPubMedCentral

47.

Bouteloup C, Desport J-C, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, Couratier P (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256:1236–1242. https://doi.org/10.1007/s00415-009-5100-zCrossRefPubMed

48.

Dupuis L, Oudart H, René F et al (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A 101:11159–11164. https://doi.org/10.1073/pnas.0402026101CrossRefPubMedPubMedCentral

49.

Qu H, Deng H, Hu Z (2013) Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediat Inflamm 2013:360190–360196. https://doi.org/10.1155/2013/360190CrossRef

50.

Laird AS, Van Hoecke A, De Muynck L et al (2010) Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One 5:e13368. https://doi.org/10.1371/journal.pone.0013368CrossRefPubMedPubMedCentral

51.

Muñoz MC, Giani JF, Mayer MA, Toblli JE, Turyn D, Dominici FP (2009) TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J Endocrinol 201:185–197. https://doi.org/10.1677/JOE-08-0276CrossRefPubMed

52.

Joardar A, Manzo E, Zarnescu DC (2017) Metabolic dysregulation in amyotrophic lateral sclerosis: challenges and opportunities. Curr Genet Med Rep 5:108–114. https://doi.org/10.1007/s40142-017-0123-8CrossRefPubMedPubMedCentral

53.

Riancho J, Berciano MT, Ruiz-Soto M, Berciano J, Landreth G, Lafarga M (2016) Retinoids and motor neuron disease: potential role in amyotrophic lateral sclerosis. J Neurol Sci 360:115–120. https://doi.org/10.1016/j.jns.2015.11.058CrossRefPubMed

54.

Rauskolb S, Dombert B, Sendtner M (2017) Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis. Neurobiol Dis 97:103–113. https://doi.org/10.1016/j.nbd.2016.04.007CrossRefPubMed

55.

Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS (1994) Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 93:1131–1139. https://doi.org/10.1172/JCI117065CrossRefPubMedPubMedCentral

56.

Friedrich N, Thuesen B, Jørgensen T et al (2012) The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 35:768–773. https://doi.org/10.2337/dc11-1833CrossRefPubMedPubMedCentral

57.

Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, Zagar M (2006) Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol 13:1340–1345. https://doi.org/10.1111/j.1468-1331.2006.01503.xCrossRefPubMed

58.

Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA, The North America ALS/IGF-I Study Group* (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49:1621–1630. https://doi.org/10.1212/wnl.49.6.1621CrossRefPubMed

59.

Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71:1770–1775. https://doi.org/10.1212/01.wnl.0000335970.78664.36CrossRefPubMedPubMedCentral

60.

Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JHJ, Dobbins T, European ALS/IGF-I Study Group* (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51:583–586. https://doi.org/10.1212/wnl.51.2.583CrossRefPubMed

61.

Beauverd M, Mitchell JD, Wokke JHJ, Borasio GD (2012) Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 11:CD002064. https://doi.org/10.1002/14651858.CD002064.pub3CrossRefPubMed

62.

Sano R, Reed JC (2013) ER stress-induced cell death mechanisms. Biochim Biophys Acta 1833:3460–3470. https://doi.org/10.1016/j.bbamcr.2013.06.028CrossRefPubMed

63.

Pfeiffer RM, Mayer B, Kuncl RW et al (2019) Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of Medicare prescription drugs. Amyotroph Lateral Scler Front Degener:1–11. https://doi.org/10.1080/21678421.2019.1682613

64.

Walker VM, Davies NM, Jones T, Kehoe PG, Martin RM (2016) Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. BMJ Open 6:e012044. https://doi.org/10.1136/bmjopen-2016-012044CrossRefPubMedPubMedCentral

65.

Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC, the GERP ALS Study Group (2012) A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 7:e37885. https://doi.org/10.1371/journal.pone.0037885CrossRefPubMedPubMedCentral

66.

Herzig S, Shaw RJ (2018) AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 19:121–135. https://doi.org/10.1038/nrm.2017.95CrossRefPubMed

67.

Liu Y-J, Chern Y (2015) AMPK-mediated regulation of neuronal metabolism and function in brain diseases. J Neurogenet 29:50–58. https://doi.org/10.3109/01677063.2015.1067203CrossRefPubMed

68.

Zhao Z, Sui Y, Gao W, Cai B, Fan D (2015) Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J Int Med Res 43:67–79. https://doi.org/10.1177/0300060514554725CrossRefPubMed

69.

Liu Y-J, Ju T-C, Chen H-M, Jang YS, Lee LM, Lai HL, Tai HC, Fang JM, Lin YL, Tu PH, Chern Y (2015) Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener 24:787–801. https://doi.org/10.1093/hmg/ddu497CrossRef

70.

Liu Y-J, Lee L-M, Lai H-L, Chern Y (2015) Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett 589:432–439. https://doi.org/10.1016/j.febslet.2014.12.029CrossRefPubMed

71.

Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, Humala N, Thiyagarajan M, Wang J, Pasinetti GM (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 7:29. https://doi.org/10.1186/1471-2202-7-29CrossRefPubMedPubMedCentral

72.

Pasinetti GM, Bilski AE, Zhao W (2013) Sirtuins as therapeutic targets of ALS. Cell Res 23:1073–1074. https://doi.org/10.1038/cr.2013.94CrossRefPubMedPubMedCentral

73.

Herskovits AZ, Guarente L (2013) Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 23:746–758. https://doi.org/10.1038/cr.2013.70CrossRefPubMedPubMedCentral

74.

Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E (2013) Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α. Neurobiol Dis 51:72–81. https://doi.org/10.1016/j.nbd.2012.07.004CrossRefPubMed

75.

Bandres-Ciga S, Noyce AJ, Traynor BJ (2019) Mendelian randomization-a journey from obscurity to center stage with a few potholes along the way. JAMA Neurol 77:7–8. https://doi.org/10.1001/jamaneurol.2019.3419CrossRef

76.

Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet Lond Engl 375:181–183. https://doi.org/10.1016/S0140-6736(09)61794-3CrossRef

77.

Gray N, Picone G, Sloan F, Yashkin A (2015) The relationship between BMI and onset of diabetes mellitus and its complications. South Med J 108:29–36. https://doi.org/10.14423/SMJ.0000000000000214CrossRefPubMedPubMedCentral

78.

Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20–24. https://doi.org/10.1002/mus.22114CrossRefPubMedPubMedCentral

79.

Moglia C, Calvo A, Grassano M, Canosa A, Manera U, D'Ovidio F, Bombaci A, Bersano E, Mazzini L, Mora G, Chiò A (2019) Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry 90:666–673. https://doi.org/10.1136/jnnp-2018-319611CrossRefPubMed

80.

Dokken BB (2008) The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes Spectr 21:160–165. https://doi.org/10.2337/diaspect.21.3.160CrossRef

81.

Chiò A, Calvo A, Ilardi A et al (2009) Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73:1681–1685. https://doi.org/10.1212/WNL.0b013e3181c1df1eCrossRefPubMed

82.

Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, Scialo C, Sorarù G, Trojsi F, Conte A, Falzone YM, Tortelli R, Russo M, Chiò A, Sansone VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurrò MR, Sabatelli M, Riva N, Logroscino G, Messina S, Fini N, Mandrioli J (2017) Factors predicting survival in ALS: a multicenter Italian study. J Neurol 264:54–63. https://doi.org/10.1007/s00415-016-8313-yCrossRefPubMed

83.

Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, The ITALSGEN Consortium, Arosio A, Barberis M, Bartolomei I, Battistini S, Benigni M, Borghero G, Brunetti M, Calvo A, Cammarosano S, Cannas A, Canosa A, Capasso M, Caponnetto C, Caredda C, Carrera P, Casale F, Cavallaro S, Chiò A, Colletti T, Conforti FL, Conte A, Corrado L, Costantino E, D'Alfonso S, Fasano A, Femiano C, Ferrarese C, Fini N, Floris G, Fuda G, Giannini F, Grassano M, Ilardi A, la Bella V, Lattante S, Logroscino G, Logullo FO, Loi D, Lunetta C, Mancardi G, Mandich P, Mandrioli J, Manera U, Marangi G, Marinou K, Marrali G, Marrosu MG, Mazzini L, Melis M, Messina S, Moglia C, Monsurro MR, Mora G, Mosca L, Occhineri P, Origone P, Pani C, Penco S, Petrucci A, Piccirillo G, Pirisi A, Pisano F, Pugliatti M, Restagno G, Ricci C, Rita Murru M, Riva N, Sabatelli M, Salvi F, Santarelli M, Sideri R, Simone I, Spataro R, Tanel R, Tedeschi G, Tranquilli S, Tremolizzo L, Trojsi F, Volanti P, Zollino M, The International ALS Genomics Consortium, Abramzon Y, Arepalli S, Baloh RH, Bowser R, Brady CB, Brice A, Broach J, Campbell RH, Camu W, Chia R, Chiò A, Cooper-Knock J, Cusi D, Ding J, Drepper C, Drory VE, Dunckley TL, Eicher JD, Faghri F, Feldman E, Kay Floeter M, Fratta P, Geiger JT, Gerhard G, Gibbs JR, Gibson SB, Glass JD, Hardy J, Harms MB, Heiman-Patterson TD, Hernandez DG, Jansson L, Kamel F, Kirby J, Kowall NW, Laaksovirta H, Landi F, le Ber I, Lumbroso S, MacGowan DJL, Maragakis NJ, Mouzat K, Murphy NA, Myllykangas L, Nalls MA, Nicolas A, Orrell RW, Ostrow LW, Pamphlett R, Pickering-Brown S, Pioro E, Pliner HA, Pulst SM, Ravits JM, Renton AE, Rivera A, Robbrecht W, Rogaeva E, Rollinson S, Rothstein JD, Salvi E, Scholz SW, Sendtner M, Shaw PJ, Sidle KC, Simmons Z, Singleton AB, Stone DC, Sulkava R, Tienari PJ, Traynor BJ, Trojanowski JQ, Troncoso JC, van Damme P, van Deerlin VM, van den Bosch L, Zinman L, Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chiò A, Traynor BJ (2019) Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 85:470–481. https://doi.org/10.1002/ana.25431CrossRefPubMedPubMedCentral

84.

Ahmed RM, Dupuis L, Kiernan MC (2018) Paradox of amyotrophic lateral sclerosis and energy metabolism. J Neurol Neurosurg Psychiatry 89:1013–1014. https://doi.org/10.1136/jnnp-2018-318428CrossRefPubMed

Title: The links between diabetes mellitus and amyotrophic lateral sclerosis
Authors: Rosario Vasta
Fabrizio D’Ovidio
Giancarlo Logroscino
Adriano Chiò
Publication date: 01-04-2021
Publisher: Springer International Publishing
Keywords: Amyotrophic Lateral Sclerosis
Insulins
Diabetes
Insulins
Published in: Neurological Sciences / Issue 4/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05099-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The links between diabetes mellitus and amyotrophic lateral sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Scientific productivity in neurology: impact of the socio-economic status

Related risk factors associated with post-stroke fatigue: a systematic review and meta-analysis

A novel homozygous splicing mutation of the AGL gene in a Chinese patient with severe myopathy involvement of glycogen storage disease type IIIa

Decreased LF/HF ratio is associated with worse outcomes in patients who received mechanical thrombectomy under general anesthesia for emergent large vessel occlusion: a retrospective study

Gastrointestinal dysfunction in movement disorders

Spinocerebellar ataxia type 48: last but not least